Business Context and Reporting Period
This Form 8-K was filed by AmerisourceBergen Corporation (now Cencora, Inc.) on December 1, 2006. The report discloses a material acquisition event occurring on the same date.
Key Financial Metrics
- Acquisition Cost: Approximately US$12.9 million in cash.
- Target Company: Access M.D., Inc. (AMD), a Canadian specialty pharmaceutical services provider.
- Target Revenue: AMD expects calendar year 2006 revenues of approximately US$6 million.
- Other Metrics: The filing does not provide consolidated revenue, profit, cash flow, margins, debt, or liquidity figures for AmerisourceBergen Corporation.
Material Changes
The primary material change is the acquisition of 100% of the outstanding stock of Access M.D., Inc. This transaction expands the Registrant's portfolio of services for specialty pharmaceutical manufacturers.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future outlook, or specific risk factors related to this transaction beyond the standard disclosure of the acquisition. No unusual items or contingencies were disclosed in this specific report.
Investor Verification Checklist
- Verify the integration timeline and expected synergies of Access M.D., Inc. into AmerisourceBergen's operations.
- Confirm the final purchase price and any potential earn-out provisions not detailed in the initial press release.
- Assess the impact of the US$12.9 million cash outlay on the company's overall liquidity position.
- Review the full text of the news release (Exhibit 99.1) for additional strategic rationale.